Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer Cell Immunoglobulin-like Receptor 2DL3 (None)
- Target
- None
- Molecular classification
- Receptor, Transmembrane glycoprotein receptor
01
Overview
KIR2DL3 is an inhibitory receptor expressed on NK cells and some T cells. It binds to specific HLA-C alleles (Cw1, Cw3, Cw7) and inhibits NK cell activation via ITIM signaling, playing a crucial role in regulating immune responses and preventing autoimmunity. Polymorphisms in KIR2DL3 and its ligands are associated with susceptibility to various diseases, including viral infections, cancer, and autoimmune conditions. Therapeutic antibodies targeting KIRs, such as Lirilumab, are under investigation for cancer treatment.
- Other names
- KIR2DL3CD158bNKAT-2
02
Mechanism of action
Upon ligand binding, ITIM motifs are phosphorylated, recruiting phosphatases (SHP‐1/SHP‐2) that dephosphorylate key signaling proteins, inhibiting cellular activation/cytotoxicity against target cells expressing compatible MHC class I molecules.
03
Biological functions
Immune responseInhibition of NK cell activityRegulation of immune responsesMaintenance of self-tolerance
04
Disease associations
Viral infections (e.g., hepatitis C)Cancer progression (e.g., prostate cancer)Graft-versus-host diseaseAutoimmune conditions
05
Safety considerations
Potential for broad immunosuppressionOff-target effects due to targeting multiple KIRs
06
Interacting drugs
Lirilumab
Beyond the preview
Go deeper on Killer Cell Immunoglobulin-like Receptor 2DL3 (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer Cell Immunoglobulin-like Receptor 2DL3 (None).